Members of Congress have sold off more than $1.2 million in UnitedHealth Group stock this year, a move that coincided with mounting federal scrutiny of the health insurance giant’s business practices, according to an investigation by Politico.
The timing of the sales has drawn attention as both congressional and administration investigations into UnitedHealth’s billing practices and care denials intensified over recent months .
The stock sales come as UnitedHealth, the nation’s largest health insurer, faces bipartisan concern over its handling of claims and patient care. Lawmakers’ financial disclosures show a flurry of transactions involving UnitedHealth shares, with several members divesting significant holdings as the company’s stock price experienced notable volatility.
The investigations into UnitedHealth focus on allegations of improper billing and the denial of care, issues that have sparked outrage among patients and providers alike. The probes have put additional pressure on the company, which has already been under the microscope for its dominant role in the health insurance market and its influence over patient access to care.
The timing of the stock sales has raised questions about whether lawmakers acted on nonpublic information or sought to avoid financial losses as UnitedHealth’s stock price declined. While members of Congress are required to disclose stock trades, the overlap between the sales and the launch of federal investigations has fueled calls for greater transparency and stricter rules governing lawmakers’ financial activities.
Dan Weiskopf, an investment portfolio manager at Tidal Financial Group who tracks congressional stock trading, told Politico that if he were an investor in the insurer, he’d “be very concerned when I saw that the regulators, as members of Congress, are dumping the stock. That’s very clearly a red flag.”
Ethics experts and watchdog groups have long warned about the potential for conflicts of interest when lawmakers hold or trade stock in companies affected by federal policy and oversight. The UnitedHealth transactions have reignited debate over proposals to ban members of Congress from owning or trading individual stocks, particularly in sectors they help regulate.
A spokesperson for UnitedHealth declined to comment to Politico on the congressional stock sales but reiterated the company’s commitment to cooperating with federal investigations and improving its practices.
The controversy comes at a time of heightened scrutiny of the relationship between lawmakers and the industries they oversee. As the probes into UnitedHealth continue, advocates are urging Congress to take action to restore public trust and ensure that elected officials are held to the highest ethical standards.
The sales and the surrounding investigations are likely to remain in the spotlight as Congress returns from its August recess and lawmakers face renewed pressure to address both health care oversight and their own financial dealings.
But the issue is the latest in a series of question being raised over the health insurance system as the costs of premiums continues to rise alarmingly.